for me, ATNM is not:
-a sexy development that wall street can super hype up like a diabetes, cancer or Alzheimer development. So its not one I have seen get a lot of attention since I first got into it in 2016 (note, till the r/split, I was trading runs for gains if I could time it, and then reload. So made something while it was essentially running flat)
-its not even a NEEDED product in that its filling a 'hole' in the health care system. To me, its a BENEFICIAL development, its making something taking place more effective. So its not going to get a lot of attention from the aspect that 'look at how big its market' will be either.
Concluding this way back in 2016, my goal from buying a lot at an initial cost basis of 25 cents, was to see it get to $3/sh on FDA approval. Now that doesn't sound like a lot, but for the share count I was planning on having, $3 was very achievable as most drug approvals see their share prices get caught up in a momentum run with $5-8 at least achieved (before folks start to question things like sales, revenues, etc)
Now? with only 11-14 Million shares outstanding? That $3 target would now be $90, cut that into a 1/3rd to be more 'reasonable' market cap, and its still around a 200% return from this price level.. I can live with ATNM being a little quiet while it finishes up. Especially since I am selling covered calls while I wait.
So to close, is there something nefarious going on? Don't know, but again, I am using Dec 2021 for the completion date of the PH 3 and because of some chatter from management themselves, kind of wondering if there might be a surprise forthcoming (smile).. (as I got on CRMD (Ph 3 halted at the interim/halfway point because of the results) which has an FDA approval date of 28 Feb, current share price of $8.5, expectations of $20-25 based on potential sales, $30-40 if they get approval to expand their market to another sector that shouldnt' require any additional trials because of the identical usage the product would apply to)
News 
Market Data 
Discover 
